Puma Biotechnology
PBYI
118 hedge funds and large institutions have $356M invested in Puma Biotechnology in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 44 increasing their positions, 43 reducing their positions, and 15 closing their positions.
28% more call options, than puts
Call options by funds: $726K | Put options by funds: $569K
2.17% more ownership
Funds ownership: 88.8% → 90.97% (+2.2%)
2% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 43
2% less capital invested
Capital invested by funds: $362M → $356M (-$6.57M)
4% less funds holding
Funds holding: 123 → 118 (-5)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$10.8M |
| 2 |
GC
Globeflex Capital
San Diego,
California
|
+$4.17M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$2.53M |
| 4 |
FAM
Fred Alger Management
New York
|
+$2.35M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.16M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$3.18M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$2.45M |
| 4 |
DM
Deerfield Management
New York
|
-$2.12M |
| 5 |
Axa
Paris,
France
|
-$1.85M |
PBYI Hedge Fund Activity: Q1 2021 in Review
118 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q1 2021, worth a combined $356M — down 1.8% from $362M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PBYI and 11 opened new positions — a net loss of 4 holders — while 43 trimmed existing stakes and 44 added.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $10.8M. The largest seller was Morgan Stanley, cutting an estimated $5.16M.
- 118 institutional investors held Puma Biotechnology (PBYI) as of Q1 2021, down from 123 in Q4 2020.
- Funds reported $356M of Puma Biotechnology stock for Q1 2021, down 1.8% quarter-over-quarter.
- 11 funds opened new Puma Biotechnology positions in Q1 2021 and 15 closed out, a net change of -4 holders.
- The largest Puma Biotechnology buyer in Q1 2021 was AIGH Capital Management, an estimated $10.8M added.
- The largest Puma Biotechnology seller in Q1 2021 was Morgan Stanley, an estimated $5.16M sold.
Based on aggregated 13F filings for Q1 2021.